Review Article · Übersichtsarbeit
Pure Red Cell Aplasia Induced by Antibodies against Human Recombinant ErythropoietinKrüger A. · Eckardt K.
Medizinische Klinik für Nephrologie und Hypertensiologie, Universitätsklinikum Erlangen und Klinikum Nürnberg, Friedrich-Alexander Universität, Erlangen-Nürnberg, Germany
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Human recombinant erythropoietin (epoetin) is a very effective and safe biopharmaceutical. However, in 1998 the incidence of pure red cell aplasia (PRCA) induced by antierythropoietin (anti-EPO) antibodies in patients treated with epoetin started to increase. PRCA is a rare condition of non-regenerative anemia which can be associated with a variety of diseases and is in some cases of immunological origin. To date the incidence rate of epoetininduced PRCA has fallen again. The temporary rise in incidence was associated with the subcutaneous use of the epoetin alpha preparation distributed outside the USA and followed a change in the formulation of this product to human serum albumin-free polysorbate 80. Among several reasons that have been explored, the most likely cause has been the contamination of the solution with organic compounds leaching from rubber stoppers of pre-filled syringes. The diagnosis of PRCA is based on typical clinical features, detection of anti-EPO antibodies and typical findings in bone marrow. In cases of suspected PRCA, epoetin medication needs to be discontinued immediately. Immunosuppressive treatment can be successful and should be initiated if possible once the diagnosis has been confirmed.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.